NASDAQ · Biotechnology · USD

Passage Bio, Inc. (PASG) Stock Analysis

Passage Bio, Inc. (PASG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PASG

$3.59

−$0.01 (−0.28%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PASG with… →

PASG Key Statistics

As of Oct 21, 2026

Trading

Open: $3.47
Previous Close: $3.60
Day's Range: 3.47–3.59
52-Week Range: 3.29–20.00
Volume: 2.90K
Beta: 1.39

Valuation

Market Cap: $11.55M
P/E Ratio: unprofitable
EPS (ttm): −11.33

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$45.52M
Shares Outstanding: 3.22M
1-Year Return: −58.97%

Dividend and dates

Avg Volume: 21.19K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PASG closed at $3.59, −58.97% over 1 year.

Passage Bio, Inc. (PASG) has a market capitalization of $11.55M.

In fiscal 2025, PASG reported revenue of $0.00.

PASG Stock Return by Calendar Year

Passage Bio, Inc. (PASG) return since Feb 2020: what $10,000 became

1 year: $10,000 $4,103; −58.97%
5 years: $10,000 $191; −98.09%
Since Feb 2020: $10,000 $81; −99.19%

If you had invested $10,000 in Passage Bio, Inc. (PASG) at the close on February 28, 2020, the earliest close on record here, it would have been worth $81 at the close on October 21, 2026: −99.19% in total, −51.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+15.18%−75.17%−78.27%−26.81%−43.86%+4.06%−69.58%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−69.58%
2025	+4.06%
2024	−43.86%
2023	−26.81%
2022	−78.27%
2021	−75.17%
2020 (partial year)	+15.18%

As of October 21, 2026.

PASG Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$45.52M	—
2024	$0.00	−$64.77M	—
2023	$0.00	−$102.06M	—
2022	$0.00	−$136.13M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$43.15M	−$45.52M	—
2024	$0.00	—	−$65.17M	−$64.77M	—
2023	$0.00	—	−$103.00M	−$102.06M	—
2022	$0.00	—	−$135.39M	−$136.13M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

Passage Bio, Inc. (PASG) is capitalised at $11.55M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 24 employees.

Over the past 52 weeks the price has ranged from $3.29 to $20.00. The most recent close on file for PASG is $3.59, dated October 21, 2026. That is −$0.01 (−0.28%) against the previous close. The latest close sits 9.12% above that 52-week low.

Financial Health

In fiscal 2025, Passage Bio, Inc. reported revenue of $0.00. The same year closed with a net loss of $45.52M. Earnings per share on a trailing basis come to −11.33.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.39. Annualized volatility over the trailing 6 years is 97.62%. The trailing one-year total return is −58.97%. Measured over 5 years, that is −54.69% a year compounded.

Growth & Income

No dividend is on file for PASG.

2026 is still running; the total return is −69.58% year to date. The strongest complete calendar year on file is 2025 at +4.06%; the weakest is 2022 at −78.27%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Passage Bio, Inc. (PASG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Passage Bio, Inc.	PASG	$11.55M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Passage Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Passage Bio, Inc.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Visit website →